

Supplementary Materials:

Radiomics-Based Outcome Prediction for Pancreatic Cancer Following Stereotactic Body Radiotherapy

Elsa Parr ^{1,†}, Qian Du ^{2,†}, Chi Zhang ², Chi Lin ¹, Ahsan Kamal ¹, Josiah McAlister ¹, Xiaoying Liang ³, Kyle Bavitz ¹, Gerard Rux ¹, Michael Hollingsworth ¹, Michael Baine ^{1,*} and Dandan Zheng ^{1,*}

¹ Radiation Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA; elsa.parr@unmc.edu (E.P.); clin@unmc.edu (C.L.); ahsan.kamal@unmc.edu (A.K.); josiah.mcallister@unmc.edu (J.D.); kyle.bavitz@unmc.edu (K.B.); GerardRux@creighton.edu (G.R.); mahollin@unmc.edu (M.H.)

² Biological Sciences, University of Nebraska Lincoln, Lincoln, NE 68521, USA; qian.du@huskers.unl.edu (Q.D.); zhang.chi@unl.edu (C.Z.);

³ Proton Institute, University of Florida, Jacksonville, FL 32206, USA; XLiang@floridaproton.org

[†] Co-first-author, contributed equally

^{*} Correspondence: mbaine@unmc.edu (M.B.); dandan.zheng@unmc.edu (D.Z)

Received: 24 March 2020; Accepted: 22 April 2020; Published: 24 April 2020




Figure S1. Area under the precision-recall curve (AUPRC) of clinical, radiomic, and combined clinical + radiomic features.




Figure S2. Data resampling and cross-validation in the developed radiomic model workflow.